Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?

It is now more than 18  years since Brenner and Hall (1) and, in the same year, Duchesne and Peters (2), independently suggested that there was a strong radiobiological rationale, specific to prostate cancer, for hypofractionating prostate cancer radiation therapy. In short, this was because the slow-growing nature of mo st prostate cancers results in their response to changes in fractionation being similar to those of the surrounding late-responding normal tissues. Consequently, as compared with standard 40-45 fraction treatment protocols for prostate cancer radiation therapy, smaller numbers of higher-dose fractio ns (with an appropriately reduced total dose) would be expected to be as clinically effective but would potentially have advantages in terms of patient convenience, economics and logistics.

Source: International Journal of Radiation Oncology * Biology * Physics - February 21, 2018 Category: Radiology Authors: David J. Brenner, Eric J. Hall Tags: Clinical Investigation Source Type: research